{"schema_version":"secwatch.filing_event.v1","accession":"0001837607-25-000013","form_type":"8-K","ticker":"AEON","cik":"0001837607","company_name":"AEON Biopharma, Inc.","filed_at":"2025-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.192877+00:00","generated_at":"2026-05-26T06:24:09.589886+00:00","sec_items":["3.03","5.03","5.07","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"AEON Biopharma approves 1-for-72 reverse stock split to maintain NYSE American listing","bullets":["Reverse split ratio of 1-for-72; effective 12:01 AM ET on February 26, 2025.","Outstanding shares reduced from ~79.9 million to ~1.1 million; fractional shares rounded up.","Authorized shares increased from 500 million to 1.04 billion at special meeting.","Ticker 'AEON' unchanged; new CUSIP 00791X 209; votes: 32.6M for, 3.6M against.","Purpose: increase share price to comply with NYSE American continued listing standards."],"urls":{"canonical":"https://secwatch.observer/filing/0001837607-25-000013","json":"https://secwatch.observer/filing/0001837607-25-000013.json","markdown":"https://secwatch.observer/filing/0001837607-25-000013.md","text":"https://secwatch.observer/filing/0001837607-25-000013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1837607/000183760725000013/0001837607-25-000013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1837607/000183760725000013/aeon-20250224x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T06:24:09.589886+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}